Washington Capital Management Inc. Purchases 7,515 Shares of Hologic, Inc. (NASDAQ:HOLX)

Washington Capital Management Inc. grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 94.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,445 shares of the medical equipment provider's stock after purchasing an additional 7,515 shares during the quarter. Hologic makes up about 0.8% of Washington Capital Management Inc.'s investment portfolio, making the stock its 29th largest holding. Washington Capital Management Inc.'s holdings in Hologic were worth $954,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Venturi Wealth Management LLC boosted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Smithfield Trust Co boosted its position in shares of Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new position in shares of Hologic during the fourth quarter worth $49,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on HOLX shares. Citigroup dropped their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Raymond James restated an "outperform" rating and set a $71.00 target price (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of "Hold" and a consensus price target of $77.42.

Insider Activity

In other news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.88% of the company's stock.

Hologic Trading Up 2.0%

Shares of HOLX opened at $64.33 on Friday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The company has a market cap of $14.34 billion, a P/E ratio of 20.29, a P/E/G ratio of 2.14 and a beta of 0.55. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company's fifty day simple moving average is $58.27 and its 200-day simple moving average is $65.35.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the firm posted $1.03 earnings per share. The business's revenue for the quarter was down 1.2% on a year-over-year basis. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.